Key result
Vaccination with the recombinant PRV variant rHN1201 TK-/gE-/gI-/11k-/28k- provided 100% survival and complete clinical protection in pigs challenged with a virulent PRV variant.
Why the study?
A re-emerging pseudorabies virus variant caused large-scale outbreaks in swine herds in China despite classical vaccine immunization.
Absolute Event Rate: 100% vs 0%
Supports candidate advancement to field trials in swine; leaves open durability, cross-protection, and commercial safety data.
In China, the re-emerging pseudorabies virus (PRV) variant has caused large-scale outbreaks of pseudorabies in swine herds with classical PRV vaccine immunization since late 2011. Here, a recombinant PRV with TK/gI/gE/11k/28k deletion was constructed based on variant HN1201 strain isolated in 2012, by the bacterial artificial chromosome infectious clones. Compared with the parental virus, the recombinant PRV rHN1201TK−/gE−/gI−/11k−/28k− showed a similar virus grown curve and exhibited smaller plaques. The vaccination of rHN1201TK−/gE−/gI−/11k−/28k− could elicit an earlier and higher level of gB antibody, and the neutralizing antibodies elicited by rHN1201TK−/gE−/gI−/11k−/28k− were effective against both PRV classical and variant strains. Clinically, the body temperature of the pigs immunized with rHN1201TK−/gE−/gI−/11k−/28k− was significantly lower than that of the classical PRV vaccine immunized pigs, and the recombinant PRV could provide effective protection against the challenge with the PRV variant. These results imply that the rHN1201TK−/gE−/gI−/11k−/28k− could be a promising vaccine candidate for the prevention of the current epidemic of pseudorabies in China.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2022) studied Pseudorabies virus (PRV) infection (n=15). rHN1201 TK-/gE-/gI-/11k-/28k- recombinant PRV vaccine vs. Bartha-K61 vaccine or unvaccinated placebo was evaluated on Survival rate after challenge with virulent PRV variant HN1201. Vaccination with the recombinant PRV variant rHN1201 TK-/gE-/gI-/11k-/28k- provided 100% survival and complete clinical protection in pigs challenged with a virulent PRV variant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: